Nerre Therapeutics


NeRRe Therapeutics is a UK based, mid-stage clinical company that has a unique tachykinin portfolio of 4 neurokinin (NK) antagonists: three NK-1 antagonists and a dual mechanism NK-1, 3 antagonist. The company is closing a Series B round of funding to support the continued clinical development of both lead assets:

1.          NK-1 antagonist Orvepitant for the treatment of Chronic Refractory Cough

2.          Dual mechanism NK-1, 3 antagonist NT-814 for the treatment of moderate to severe Postmenopausal Vasomotor Symptoms as the lead and gateway Women's Health indication.

Both compounds are potent, selective, orally administered small-molecules, spun outof GSK, for which important development risks have already been discharged. Both molecules have a multi-layered IP estate fully owned by NeRRe.

Stevenage Bioscience Catalyst is the UK's leading open innovation campus with a focus on therapeutics.

Learn more

We use cookies to improve our site experience. Press accept to agree to our Cookie Policy. If you decline, your information won’t be tracked when you visit this website. A single cookie will be used in your browser to remember your preference not to be tracked.